Skip to main content

Advertisement

Table 4 Rate of safety outcomes in HCV/HIV coinfected patients

From: Effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir for HCV in HIV/HCV coinfected subjects: a comprehensive analysis

Outcomes Safety Heterogeneity Studies
  Total, n/N Rate%(95%CI) I2(%) P  
Virological breakthrough 7/741 0.2 (0.0–1.0) 0 0.78 7
Virologica relapse 8/741 0.3 (0.0–1.2) 0 0.72 7
Discontinuation due to AE 2/678 0.0 (0.0–0.1) 0 0.52 6
AEs 301/460 73.9 (38.1–97.6) 98 < 0.01 3
SAEs 16/460 2.7 (0.0–9.5) 85 < 0.01 3
  1. *OBV ombitasvir, PTV paritaprevir, r ritonavir, DSV dasabuvir, RBV ribavirin, CI confidence interval, AEs adverse events, SAEs serious adverse events